EU to slap big fine on French drugmaker Servier: sources

July 8, 2014

The EU is expected to inflict a heavy fine in the coming days on French drugs giant Servier for colluding to delay a cheaper version of a popular blood-pressure treatment, sources close to the matter told AFP on Tuesday.

The European Commission will decide on the fine before the end of the month, the sources said. Israeli generic giant Teva and three other companies are also involved in the case.

Servier is suspected of trying to delay the of perindopril, a cardio-vascular medicine. The allegation is the result of a broad EU probe into the pharmaceutical industry launched in 2008.

Generic products are far cheaper than brand medicines—on average generics cost 40 percent less two years after they enter the market—and are a huge savings to patients and while remaining just as effective.

In so-called pay-for-delay deals, drug makers pay generic rivals to thwart the introduction of cheaper versions of blockbuster drugs for an agreed time.

If Servier is found guilty in the collusion it faces heavy fines of up to 10 percent of the group's total annual sales.

A year ago, Danish drugmaker Lundbeck was fined 93.8 million euros by the Commission for striking a 2002 agreement to delay the generic version of its popular anti-depressant, citalopram.

Explore further: EU fines pharma firms over generics delay (Update)

Related Stories

EU fines pharma firms over generics delay (Update)

June 19, 2013
(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives to a ...

Pfizer, Teva reach deal to allow generic Viagra

December 17, 2013
Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

High court weighs drug companies' generics policy

March 25, 2013
(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

US: 'Pay to delay' generic drugs can be illegal (Update)

June 17, 2013
The Supreme Court ruled Monday that deals between pharmaceutical corporations and their generic drug competitors, which government officials say keep cheaper forms of medicine off the market, can be sometimes be illegal and ...

FDA approves generic version of celebrex

June 3, 2014
(HealthDay)—The U.S. Food and Drug Administration on Friday gave its approval to the first generic version of the pain reliever Celebrex (celecoxib).

EU anti-trust probe maintained on Johnson & Johnson, Novartis

January 31, 2013
European anti-trust authorities said Thursday they had sent written objections to pharamaceutical giants Johnson & Johnson and Novartis over a deal affecting generic medicine.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.